Novel Molecular Approaches in Heart Failure: Seven Trans-Membrane Receptors Signaling in the Heart and Circulating Blood Leukocytes

Frontiers in Cardiovascular Medicine

Volumn 2, Issue , 2015, Pages

  Schiattarella, Gabriele Giacomo ^a   Magliulo, Fabio ^a   Cattaneo, Fabio ^a   Gargiulo, Giuseppe ^a   Sannino, Anna ^a   Franzone, Anna ^b   Oliveti, Marco ^a   Perrino, Cinzia ^a   Trimarco, Bruno ^a   Esposito, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

cardiac remodeling; heart failure; leukocytes; seven trans membrane receptors

Indexed keywords

EID: 84983381151     PISSN: None     EISSN: 2297055X     Source Type: Journal    
DOI: 10.3389/fcvm.2015.00013     Document Type: Review

References (47)

1. Liu L, Eisen HJ. Epidemiology of heart failure and scope of the problem. Cardiol Clin (2014) 32(1):1–8,vii.10.1016/j.ccl.2013.09.00924286574
2. Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L, Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol (2011) 50(3):522–33.10.1016/j.yjmcc.2010.12.02121219908
3. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol (2000) 35(3):569–82.10.1016/S0735-1097(99)00630-010716457
4. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation (1993) 87(3):755–63.10.1161/01.CIR.87.3.7558443896
5. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation (2002) 105(1):85–92.10.1161/hc0102.10136511772881
6. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature (2002) 415(6868):206–12.10.1038/415206a
7. Cattaneo F, Guerra G, Parisi M, De Marinis M, Tafuri D, Cinelli M, et al. Cell-surface receptors transactivation mediated by G protein-coupled receptors. Int J Mol Sci (2014) 15(11):19700–28.10.3390/ijms151119700
8. Gurevich VV, Gurevich EV. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther (2006) 110(3):465–502.10.1016/j.pharmthera.2005.09.00816460808
9. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science (2001) 294(5545):1307–13.10.1126/science.106386611588219
10. Perrino C, Rockman HA. Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. Curr Opin Cardiol (2007) 22(5):443–9.10.1097/HCO.0b013e3282294d7217762546
11. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure – the whys and wherefores. Heart Fail Rev (2006) 11(1):83–92.10.1007/s10741-006-9196-216819581
12. Jankowska EA, Ponikowski P, Piepoli MF, Banasiak W, Anker SD, Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure – pathophysiological links. Cardiovasc Res (2006) 70(3):434–45.10.1016/j.cardiores.2006.01.01316480965
13. Yamada S, Ohkura T, Uchida S, Inabe K, Iwatani Y, Kimura R, et al. A sustained increase in beta-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy. Life Sci (1996) 58(20):1737–44.10.1016/0024-3205(96)00155-58637398
14. Dzimiri N, Basco C, Moorji A, Afrane B, Al-Halees Z. Characterization of lymphocyte beta 2-adrenoceptor signalling in patients with left ventricular volume overload disease. Clin Exp Pharmacol Physiol (2002) 29(3):181–8.10.1046/j.1440-1681.2002.03625.x11906480
15. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol (2003) 65:81–101.10.1146/annurev.physiol.65.092101.14224912500970
16. Werner C, Werdan K, Ponicke K, Brodde OE. Impaired beta-adrenergic control of immune function in patients with chronic heart failure: reversal by beta1-blocker treatment. Basic Res Cardiol (2001) 96(3):290–8.10.1007/s00395017006011403423
17. Kohm AP, Sanders VM. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev (2001) 53(4):487–525.11734616
18. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring PA, et al. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res (2003) 93(10):e124–35.10.1161/01.RES.0000102404.81461.2514576195
19. Colucci WS, Alexander RW, Williams GH, Rude RE, Holman BL, Konstam MA, et al. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med (1981) 305(4):185–90.10.1056/NEJM1981072330504026113543
20. Frangogiannis NG. The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol (2014) 63(3):185–95.10.1097/FJC.000000000000000324072174
21. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 204(12):3037–47.10.1084/jem.2007088518025128
22. Anzai A, Anzai T, Nagai S, Maekawa Y, Naito K, Kaneko H, et al. Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling. Circulation (2012) 125(10):1234–45.10.1161/CIRCULATIONAHA.111.05212622308302
23. Yu Q, Watson RR, Marchalonis JJ, Larson DF. A role for T lymphocytes in mediating cardiac diastolic function. Am J Physiol Heart Circ Physiol (2005) 289(2):H643–51.10.1152/ajpheart.00073.200516014617
24. Yndestad A, Ueland T, Oie E, Florholmen G, Halvorsen B, Attramadal H, et al. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation (2004) 109(11):1379–85.10.1161/01.CIR.0000120704.97934.4114993131
25. Cheng X, Liao YH, Ge H, Li B, Zhang J, Yuan J, et al. TH1/TH2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol (2005) 25(3):246–53.10.1007/s10875-005-4088-015981090
26. Cheng X, Ding Y, Xia C, Tang T, Yu X, Xie J, et al. Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure. J Card Fail (2009) 15(2):158–62.10.1016/j.cardfail.2008.10.001
27. Levick SP, Goldspink PH. Could interferon-gamma be a therapeutic target for treating heart failure? Heart Fail Rev (2014) 19(2):227–36.10.1007/s10741-013-9393-823589353
28. Tian X, Zhang L, Hou Y, Xu W, Dong Y, Liu J, et al. Effects of cAMP and beta-adrenergic receptor antagonists on the function of peripheral T helper lymphocytes in patients with heart failure. Neuroimmunomodulation (2011) 18(2):73–8.10.1159/00031937520938210
29. Feldman RD, Limbird LE, Nadeau J, Robertson D, Wood AJ. Leukocyte beta-receptor alterations in hypertensive subjects. J Clin Invest (1984) 73(3):648–53.10.1172/JCI1112556323524
30. Peng Y, Ma S, Zhang S, Li Y, Yang L, Bian S. Clinical significance of changes in beta-adrenoreceptors in peripheral lymphocytes in patients with essential hypertension. Chin Med J (Engl) (2000) 113(12):1064–7.11776136
31. Ricci A, Bronzetti E, Conterno A, Greco S, Mulatero P, Schena M, et al. alpha1-adrenergic receptor subtypes in human peripheral blood lymphocytes. Hypertension (1999) 33(2):708–12.10.1161/01.HYP.33.2.70810024333
32. Brodde OE, Prywarra A, Daul A, Anlauf M, Bock KD. Correlation between lymphocyte beta 2-adrenoceptor density and mean arterial blood pressure: elevated beta-adrenoceptors in essential hypertension. J Cardiovasc Pharmacol (1984) 6(4):678–82.10.1097/00005344-198407000-000206206325
33. Feldman RD, Lawton WJ, McArdle WL. Low sodium diet corrects the defect in lymphocyte beta-adrenergic responsiveness in hypertensive subjects. J Clin Invest (1987) 79(1):290–4.10.1172/JCI1127973025262
34. Swanson MA, Lee WT, Sanders VM. IFN-gamma production by Th1 cells generated from naive CD4+ T cells exposed to norepinephrine. J Immunol (2001) 166(1):232–40.10.4049/jimmunol.166.1.23211123297
35. Gage JR, Fonarow G, Hamilton M, Widawski M, Martinez-Maza O, Vredevoe DL. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation (2004) 11(3):173–80.10.1159/00007676615067208
36. Gros R, Chorazyczewski J, Meek MD, Benovic JL, Ferguson SS, Feldman RD. G-Protein-coupled receptor kinase activity in hypertension: increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension (2000) 35(1 Pt 1):38–42.10.1161/01.HYP.35.1.3810642272
37. Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Margulies KB, Leosco D, et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J (2005) 26(17):1752–8.10.1093/eurheartj/ehi42916055494
38. Izzo R, Cipolletta E, Ciccarelli M, Campanile A, Santulli G, Palumbo G, et al. Enhanced GRK2 expression and desensitization of betaAR vasodilatation in hypertensive patients. Clin Transl Sci (2008) 1(3):215–20.10.1111/j.1752-8062.2008.00050.x20443852
39. Perrino C, Schroder JN, Lima B, Villamizar N, Nienaber JJ, Milano CA, et al. Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure. Circulation (2007) 116(22):2571–9.10.1161/CIRCULATIONAHA.107.70651517998459
40. Gao WQ, Han CG, Zhao YX, Wang Q, Zhu P, Yang TS, et al. [Effect of metoprolol on the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure]. Nan Fang Yi Ke Da Xue Xue Bao (2010) 30(5):1132–3.20501412
41. Gao WQ, Ma JL, Han CG, Wang Q, Zhu P, Yang TS. [Lymphocyte GRK2 expression of the very elderly with chronic heart failure]. Zhongguo Ying Yong Sheng Li Xue Za Zhi (2010) 26(2):207–9.20684281
42. Pandalai PK, Bulcao CF, Merrill WH, Akhter SA. Restoration of myocardial beta-adrenergic receptor signaling after left ventricular assist device support. J Thorac Cardiovasc Surg (2006) 131(5):975–80.10.1016/j.jtcvs.2006.01.02716678578
43. Hata JA, Williams ML, Schroder JN, Lima B, Keys JR, Blaxall BC, et al. Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail (2006) 12(5):360–8.10.1016/j.cardfail.2006.02.01116762799
44. Akhter SA, D’Souza KM, Malhotra R, Staron ML, Valeroso TB, Fedson SE, et al. Reversal of impaired myocardial beta-adrenergic receptor signaling by continuous-flow left ventricular assist device support. J Heart Lung Transplant (2010) 29(6):603–9.10.1016/j.healun.2010.01.01020202864
45. Rengo G, Galasso G, Femminella GD, Parisi V, Zincarelli C, Pagano G, et al. Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. Eur J Prev Cardiol (2014) 21(1):4–11.10.1177/204748731349165623689525
46. Esposito G, Perrino C, Schiattarella GG, Belardo L, di Pietro E, Franzone A, et al. Induction of mitogen-activated protein kinases is proportional to the amount of pressure overload. Hypertension (2010) 55(1):137–43.10.1161/HYPERTENSIONAHA.109.13546719901160
47. Centonze D, Battistini L, Maccarrone M. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des (2008) 14(23):2370–2342.10.2174/13816120878574001818781987